The benefit received from the new generation of prostate cancer hormonal treatments like enzalutamide (Xtandi) is time-limited. The normal course of events is that a man will develop resistance to the drug.
According to researchers, the drug Metformin, when given alone or in combination, will reverse resistance and to Xtandi in certain mice models.
The researchers have proposed that the combination of metformin with enzalutamide could be a more efficacious therapeutic strategy for the treatment of castration-resistant prostate cancer than the current standard of care. Of course, this theory needs to be evaluated in a clinical trial.
Cell Death Dis. 2017 Aug 24;8(8):e3007. doi: 10.1038/cddis.2017.417.
Liu Q1, Tong D1, Liu G1, Xu J1, Do K2, Geary K2, Zhang D2, Zhang J1, Zhang Y1, Li Y1, Bi G1, Lan W1, Jiang J1.
PMID: 28837141
Joel T. Nowak, MA, MSW wrote this Post. Joel is the CEO/Executive Director of Cancer ABCs. He is a Cancer Thriver diagnosed with five primary cancers - Thyroid, Metastatic Prostate, Renal, Melanoma, and the rare cancer Appendiceal cancer.
